The Terry Fox Research Institute and the Marathon of Hope Cancer Centres Network congratulate Dr. Lillian Siu on being elected president of the American Association for Cancer Research
The Terry Fox Research Institute and the Marathon of Hope Cancer Centres Network congratulate Dr. Lillian Siu, member of the MOHCCN Steering Committee and lead of the Princess Margaret Cancer Consortium, on being elected president of the American Association for Cancer Research (AACR).
Dr. Siu, a senior medical oncologist and senior scientist at the Princess Margaret Cancer Centre in Toronto, was elected by AACR members to serve as president for the 2024-2025 period. She will become President-Elect on April 8 of this year and will assume the full presidency of AACR in April 2025.
“We congratulate Dr. Siu on being elected by her peers to take this incredibly prestigious position,” said Dr. Jim Woodgett, President and Scientific Director of the Terry Fox Research Institute. “Dr. Siu embodies Terry Fox’s spirit on a daily basis: her commitment to transform the lives of cancer patients in the clinic and in the lab are world-class, and there is no doubt that that she will bring her knowledge, energy and enthusiasm to her new role as president of the AACR.”
“I can’t congratulate Dr. Siu enough on this incredible achievement,” said Dr. André Veillette, Executive Director of the Marathon of Hope Cancer Centres Network. “Dr. Siu is an incredible oncologist, researcher and administrator and we are honoured to have her play a central role in the Marathon of Hope Cancer Centres Network’s Team Canada of Cancer Research. Having one of our members be named to such a prestigious position is a testament to the incredible talent that makes up our Network.”
“AACR members are incredibly fortunate to have selected Dr. Lillian Siu as their next president,” said Dr. Bradly Wouters, Executive Vice President of Science and Research at the University Health Network and co-lead of the MOHCCN's Princess Margaret Cancer Consortium with Dr. Siu. “Lillian has been a tremendous researcher, clinician, and leader at the Princess Margaret Cancer Centre for many years. Her work has led to the development of effective precision therapies for patients, and has helped shape the ambition and impact of the work of all her colleagues. She will be a fantastic leader for the global cancer research community.”
Read the full press release from the AACR here.
Dr. Siu's commitment to transform the lives of cancer patients in the clinic and in the lab are world-class, and there is no doubt that that she will bring her knowledge, energy and enthusiasm to her new role as president of the AACR.
Related Team Member
-
Lillian
MOHCCN Steering CommitteeInstitutional LeadConsortium LeaderWorking Group ChairWorking Group MemberResearcher
Siu
-
Regional Consortia
Princess Margaret Cancer Consortium
- Ontario
The Princess Margaret Cancer Consortium coalesces the expertise and efforts of clinicians, pathologists, software developers and data and translational scientists to help accelerate precision medicine...Read more
Related News
-
PM2 CAN-IMPACT-IO a national immunotherapy biospecimen collection study has now opened
PM2 CAN-IMPACT-IO is a unique national initiative to measure, predict and assess cancer treatment outcomes in patients who have been treated with immunotherapy. Patients on CCTG clinical trials who co... -
Our Network reaches new heights! A letter from Dr. André Veillette
Dr. André Veillette, Executive Director of the MOHCCN, provides an update on the exciting achievement from across our Network. -
Network names four outstanding early-career clinician-scientists as recipients of its 2024 MOHCCN Clinician-Scientist Awards
Four promising, early-career clinician-scientists from Alberta, Ontario and Quebec have been named recipients of the 2024 Clinician-Scientist Awards, funded by the Marathon of Hope Cancer Centres Netw... -
Network names 10 early-career data scientists as recipients of its 2024 Health Informatics & Data Science Awards
Each will receive $40,000 from the Network over the next year to be matched by their host institutions for a total of $80,000 to support groundbreaking research in precision oncology.